Pegasys in Patients With Chronic Myeloid Leukemia (CML)
NCT01392170
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class
Stopped
Slow Accrual
Conditions
Leukemia
Interventions
DRUG:
PEG-IFNá-2a
Sponsor
M.D. Anderson Cancer Center